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Introduction
Over the last 20 years radiation oncology has been
exposed to a multitude of exciting biological and technical
developments that have a potential to significantly
improve the outcomes of cancer treatment. On the one
hand our understanding of various aspects of cancer
biology has been greatly improved by spectacular
discoveries in molecular biology and genomics. On the
other hand the progress in technology dramatically
improved the quality and utility of imaging tumor and
normal tissues and the methods of delivery sophisticated
treatments. A good example of the former is a new field
of Molecular Imaging. For example, Positron Emission
Tomography (PET) allows imaging of the metabolic
activity of tumor cells and the volumetric distribution of
clonogens. Examples of the latter are the Multi-Leaf
Collimator (MLC) and Intensity Modulated Radiation
Therapy (IMRT) that allow “sculpting” of dose distribu-
tion to conform to the target volume while sparing as
much as possible the surrounding critical normal
structures. These new developments and tools available to
practitioners of radiation oncology can greatly benefit
the patients but they also present new challenges. It is
probably an accurate statement that the progress in
technologies related to cancer care has been faster than
our comprehensive understanding of the consequences
of using these technologies. For example, these days
radiation oncologists involved in the state-of-the-art
radiation therapy can be faced with complex computer
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Over the last 20 years radiation oncology has been exposed to exciting biological and technical developments that have
a potential to significantly improve the outcomes of cancer treatment. These developments present new opportunities but also
create new challenges for the practitioners of radiation oncology. New tools, methods and techniques are required to fully utilize
these developments to create, evaluate and optimize the process of radiation treatment. Here a number of tools for planning
modern radiation therapy are presented and discussed. In particular, the need for biological considerations in the treatment
planning process is emphasized and a concept of Equivalent Uniform Dose (EUD) based on modeling of cell survival and
tissue architecture is described. Examples of IMRT dose distributions for a head and neck cancer developed using purely
dosimetric (that is, dose and dose-volume) considerations and using EUD-based considerations are shown.
Nowoczesna radioterapia – wp∏yw osiàgni´ç w dziedzinie fizyki i biologii na planowanie leczenia
W ciàgu ostatnich 20 lat radioterapia onkologiczna uleg∏a znacznemu rozwojowi dzi´ki fascynujàcym osiàgni´ciom, tak
w dziedzinie biologii, jak i w zakresie rozwiàzaƒ technicznych. Zmiany te mogà znaczàco przyczyniç si´ do poprawy wyników
leczenia chorób nowotworowych. Niemniej wszelkie zmiany nie tylko stwarzajà nowe mo˝liwoÊci, ale stanowià same w sobie
wyzwanie. Aby w pe∏ni wykorzystaç nowoÊci, potrzebny jest udoskonalony sprz´t, nowe metody i techniki post´powania – tylko
wtedy b´dzie mo˝na utworzyç, oceniç i zoptymalizowaç nowe formy radioterapii. W pracy przedstawiono i omówiono nowe
mo˝liwoÊci w zakresie planowania leczenia, a w szczególnoÊci potrzeb´ uwzgl´dnienia uwarunkowaƒ biologicznych w proce-
sie planowania leczenia. Omówiono równie˝ ide´ Jednolitej Dawki Ekwiwalentnej (Equivalent Uniform Dose – EUD),
która powsta∏a w oparciu o modelowanie prze˝ycia komórek i struktur tkankowych. Przedstawiono równie˝ przyk∏ady dystry-
bucji dawek przy zastosowaniu metody modulowania dawki (Intensity Modulated Radiation Therapy – IMRT) w leczeniu no-
wotworów g∏owy i szyi, która powsta∏a w oparciu o uwarunkowania wy∏àcznie dozymetryczne (dawka i dawka/obj´toÊç),
z uwzgl´dnieniem Jednolitych Dawek Ekwiwalentnych (EUD).
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“optimized” and “individualized” treatment plans that
are very different from the conventional treatment plans,
and for which there is none or very limited experience. As
is the case with all new technologies there is a great
expectation of progress but prudence and critical assess-
ment should be also exercised because on the receiving
end of this process are patients under our care.
Here I will discuss only one but important aspect of
modern radiation oncology, namely, the methods and
tools to assess, compare, and evaluate radiation treatment
plans. A radiation treatment plan is a multidimensional
object. This is rather obvious considering that patient's
anatomy is three-dimensional (3D) and that the treatment
agent, namely radiation dose, is not only distributed
in a highly non-uniform fashion within the 3D anatomy
but also it is distributed in time. Before the 3D era in
radiation oncology a description of radiation treatment
was, by necessity, rather simple. For example, one could
say that the patient received 60 Gy in 30 fractions of 2 Gy
per fraction. These days such simple descriptions should
be considered inadequate. Any image-based 3D computer
radiotherapy planning system provides volumetric
information about all important irradiated structures of
interest. From viewing 3D dose distributions superimposed
onto 3D anatomical structures one can easily appreciate
the fact that the actual dose distributions are never
uniform, especially for normal structures, therefore
cannot be adequately described by a single number. The
volumetric and temporal dose inhomogeneity creates
problems for reporting, evaluating and comparing rival
dose distribution. On the one hand 3D objects cannot be
directly compared and ranked without assigning a single
number to describe each object. On the other hand,
treatment outcomes depend on several biological and
dosimetric parameters in a complex manner that despite
significant advances in radiobiology is still rather poorly
understood.
To better appreciate the type of treatment planning
tools that are needed to evaluate the quality of a given
radiation treatment plan it is essential to spell out the
goals and desired outcomes of radiation therapy. Then, it
follows that the ultimate goal of radiation therapy
planning is to create a dose distribution that maximizes
the likelihood of a desired outcome of radiation therapy.
In radical radiotherapy the desired outcome is eradication
of the tumor while sparing healthy normal organs and
tissues. It follows then that a dose distribution can be
judged “good” only when the resulting clinical outcome of
radiation therapy is “good.” Hence, it seems obvious that
the clinical value of a planned dose distribution cannot be
evaluated without at least some quantitative consideration
of the clinical consequences of dose and dose-volume
effects. But how difficult it is to define “good” or, better
yet, “optimal” dose distribution? For example, the IMRT
requires algorithm-based computer optimization. That
is, it requires specifying the goals of radiation treatment in
terms understandable to the optimization algorithm. This
task is more difficult than it seems. The physicists or
dosimetrists designing treatment plans generally assume
that the dose prescription provided by radiation
oncologist (or by a treatment protocol) represents
a complete set of aims of the optimization as well as the
reference point for plan evaluation. Although such
a comfortable assumption seems obvious and understan-
dable it is important to recognize the associated problems.
First, the dose and dose-volume prescriptions are never
complete. This is particularly evident in IMRT where
there are many more degrees of freedom than in the
conventional radiotherapy, and where there are countless
significantly different dose distributions that all satisfy
the limited set of dose and dose-volume constraints.
These different dose distributions may correspond to
significantly different clinical outcomes. Second, the
clinicians are first to admit that the prescribed dose levels
that they use for plan specification and to characterize
dose and dose-volume effects in tumors and normal
tissues are often appreciably uncertain, particularly when
used in novel settings such as IMRT. On the other hand,
the physicists and, especially, the computer optimization
programs tend to consider those dose and dose-volume
constraints as infinitely precise. Third, even when dose
and dose-volume constraints entirely describe the desired
dose distribution they are often not completely satisfied
by the optimized plan. In that case it is important how the
deviations from the prescription are evaluated and
penalized and how they are weighted against each other.
Fourth, there is an obvious antagonistic relationship
between an optimal strategy for tumors (higher dose is
better, cold spots are bad) and an optimal strategy for
normal tissues (lower dose is better, hot spots are bad).
The optimal balance between the tumor and the critical
normal organs is a complex issue involving biological
considerations and clinical judgment. The optimal relative
weighting of various normal critical structures is not
predetermined but it depends on the structures involved
and the magnitude of the departure from the prescription.
Clearly, in all non-trivial cases, regardless of the planning
approach (either so-called inverse or so-called forward)
the optimization and planning process are iterative and
require clinically relevant plan evaluation tools and critical
judgment.
Materials and methods
Since the discovery of radioactivity and X-rays the practitioners
of radiation oncology have been involved in measuring,
estimating, and calculating dose. Therefore, the physical dose has
been the primary parameter that describes the extent or the
magnitude of treatment that a patient receives. Qualitatively
the relationship between dose and the resultant effect is fairly
simple – more dose corresponds to more tissue damage for both
tumors and normal organs and tissues. Therefore, dose-based
treatment planning tools have been extensively used in 2D, 3D as
well as in IMRT treatment planning. In modern treatment
planning environment these tools include various simple dose
statistics such as the minimum, the maximum, the mean/median
dose for any Volume of Interest (VOI), or say, dose to 95% of
the target volume. A convenient tool to summarize and visualize
a volumetric characteristic of a dose distribution is Dose-Volume
Histogram (DVH) that displays a percentage of the VOI
receiving a certain dose [1, 2]. Although the spatial information
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is lost when a 3D dose distribution is reduced to a 2D graph, the
DVH concept has been effectively used to quickly compare rival
dose distributions and represents a standard tool in all 3D
treatment planning systems [3-5].
The dose-based tools are time-honored and practitioners of
radiotherapy are quite comfortable using them not only to
evaluate treatment plans but also to design treatment plans by
explicitly expressing treatment goals in terms of dose and dose-
volume requirements and constraints. However, sooner or later
one discovers that relying exclusively on dose and dose-volume-
based considerations is not sufficient even in apparently simple
situations. Figure 1 shows an example. Here, there are two target
volume DVHs. One was obtained using two parallel-opposed
(AP-PA) open fields and the other one represents an optimized
IMRT plan. Both dose distributions are normalized to the same
mean dose in the target volume (represented by the DVHs in
Figure 1). The IMRT plan was derived using a sophisticated
optimization algorithm with the score function designed to
minimize the target dose inhomogeneity by minimizing the sum
of squared deviations from the prescribed (mean) dose. Nothing
was optimized for the AP-PA plan and both field weights are
equal. The corresponding DVHs intersect twice. There are two
interesting and important questions; 1) which target dose
distribution is more uniform? 2) which target dose distribution is
better? It is clear that even the simpler first question has no
satisfactory answer because the answer depends on our
definition of dose uniformity. There are at least two equally
reasonable definitions. The first one says that a dose distribution
is more uniform if the corresponding standard deviation of dose
is lower. According to this definition the IMRT DVH
corresponds to a more uniform dose distribution (2.5 Gy versus
3.5 Gy). This is not surprising since the IMRT plan was derived
by effectively minimizing the standard deviation of dose.
However, equally reasonable measure of dose uniformity is the
range of doses. According to this definition the AP-PA dose
distribution is more uniform (a range of 28 Gy versus 35 Gy). It
is also clear that answering the second question is more
complicated and, in fact, it is beyond the scope of purely
dosimetric considerations, namely, for the reason that dose is
only a surrogate (although, often, a very good one) of clinical
and biological considerations. In fact, it is easy to define
a criterion by which one can tell which dose distribution is better.
It is the one that provides a higher chance of eradicating all the
clonogens. In other words, to tell which target dose distribution
is better one needs a tool that estimates the Tumor Control
Probability (TCP). A similar situation presents for normal
structures. A normal tissue dose distribution is better if the
corresponding Normal Tissue Complication Probability (NTCP)
is lower.
There are several models of TCP and NTCP [6-22]. Most
of these models are mechanistic in a sense that they try to model
the presumed mechanism of tissue damage by modeling cell kill
statistics and tissue architecture. The former is often modeled
using the Linear-Quadratic (LQ) model that assumes that the
frequency of biologically relevant effects of radiation, E, as
a function of dose, D, can be expressed by a quadratic function,
E=aD + bD2, where a and b are model parameters [23-25].
The latter is often modeled using the concept of Functional
Subunit (FSU) and the manner, parallel or serial, that these
FSUs are arranged in a tissue or organ [26]. Some models
are phenomenological in a sense that they use convenient
mathematical formulae to describe the dependence of the
probability of outcome of interest (i.e., TCP, NTCP) on the
dose, volume, and time parameters without interpreting these
formulae in any mechanistic sense, and without interpreting the
model parameters in terms of realistic biological entities [11, 27].
Both types of models have been used in various investigations
but their clinical use has been limited due to the problems with
clinical validation of these models. In order to validate a model
one needs a good quality data set or, better yet, several sets
that allow estimation of the model parameters with reasonable
accuracy and formal testing of the consistency of the model with
the data [28]. Additionally, the biological mechanism of tissue
response to radiation is very complex and not fully understood,
and even the mechanistic biological models are incomplete and
describe only what is assumed to be the most important effects.
Despite the mentioned problems the models of TCP and NTCP
have been shown to be useful for plan evaluation and
optimization particularly for IMRT where a vast space of
possible treatment plans requires computers to search for the
best option [29]. This is possible because for plan optimization
one needs to compare only the relative merits of rival plans and
ranking of plans using these models can be fairly robust.
The purely dosimetric treatment planning tools are
relatively simple, well understood, and can be effectively used in
a variety of situations. However, as mentioned above, they
represent only surrogates of clinically relevant characteristics
of a treatment plan. On the other hand models of tissue response
to radiation have potential to describe the actual clinical and
biological consequences of any radiation treatment but they try
to model mechanisms that are not fully understood and their
parameters are rather uncertain due to the weaknesses and
incompleteness of the relevant clinical data. To fill the gap
between the two approaches we developed a concept of
Equivalent Uniform Dose (EUD) [30]. The concept of EUD
assumes that any two dose distributions are equivalent if they
cause the same specified clinical or radiobiological effect. The
clinically relevant effects vary from one normal tissue/organ to
another and from tumors to normal tissues. Below we describe
the cell-survival-based models for tumors and for normal tissues.
For tumors it is generally accepted that to locally control
a tumor all clonogens need to be killed. Therefore, the
probability of local control as a function of dose depends on
the expected number of surviving clonogens. Assuming that
each voxel (sub-volume) of the tumor responds to radiation
independently the probability of controlling all (say, N) voxels, P,
is the product of the probabilities taken over all voxels of the
target volume:
N
P=PP(Di),
i=1
where Di is the dose at the i'th voxel and P(Di) is the probability
that all clonogens within the i'th voxel are killed. For doses
typically used in curative radiation therapy the probability of
survival for a single clonogen is very small and the number of
clonogens is relatively large. Therefore, the Poisson statistics of
Figure 1. An example of dose-volume histograms for a target volume for
IMRT dose delivery (Plan #1 – solid line) and for standard two parallel-
opposed fields (Plan #2 – dashed line). A table shows the corresponding
standard deviations of the target dose and the range of doses within the
target volume.
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events can be applied and the probabilities P(Di) can be modeled
as
P(Di)=exp[–ni NSF(Di)],
where ni=
1–N is the partial volume of a voxel and SF(Di) is the
survival fraction of clonogens exposed to dose Di. EUD can be
also calculated from the corresponding differential DVH. In
this case ni is the relative size of the i’th dose bin corresponding
to dose Di and N is the number of bins.
Modeling cell survival has a long tradition and the most
widely accepted model is the Linear-Quadratic (LQ) model.
According to the LQ model, the surviving fraction of cells
irradiated to dose D, SF(Di), for fractionated irradiation is
calculated as
DiSF(Di)=exp[–Di(a+b –– )], (1)M
where a and b are the parameters of the LQ model and M is the
number of fractions. For perfectly uniform target dose distribu-
tion the same formulae can be used. That is,
P(EUD)=exp[–NSF(EUD)]
and
EUDSF(EUD)=exp[–EUD(a+b ––––––)]M
where EUD is the corresponding unknown equivalent dose.
From the definition of EUD, the probabilities of tumor control
for the inhomogeneous dose distribution and for the uniform
dose distribution should be equal. Therefore, the following
equation must hold:
N
PP(Di)=P(EUD).
i=1
First, one can notice that the total number of clonogens, N,
cancels out. That is, the formula holds for any density of
clonogens or size of the tumor. Second, by taking twice the
natural logarithm of both sides a quadratic equation for EUD is
obtained:
EUD
N DiEUD(a+b –––––)=–lnS ni exp[–Di(a+b –––)].M i=1 M
This equation can be easily solved for EUD and dose-volume
and dose per fraction effects can be studied for different tumor
radiosensitivities (that is, for different values of a and b) and for
different fractionation schemes (that is, for different values of
M).
Based on various and admittedly incomplete clinical data
the value of the parameter b for tumors is often an order of
magnitude smaller than the value of the parameter a (with
a possible notable exception of prostate carcinoma [31]). In this
situation the quadratic term of the LQ model can be disregarded
and the EUD formula simplifies to:
N
lnS ni exp(–aDi)
i=1EUD=– –––––––––––––––– (2)a
If one prefers to describe cell radiosensitivity using SF2
(the fraction of clonogens surviving a single dose of 2Gy)
formula (2) has another form,
N
lnS ni (SF2)Di/2Gy
i=1EUD=2Gy –––––––––––––––– ,
ln(SF2)
which is obtained by noticing that SF2=exp(–2a). Formula (2)
has been proposed as a basic formula for optimization of dose
distribution when the temporal distribution of dose is set and the
only variable is the volumetric distribution of dose.
The value of EUD for any inhomogeneous target dose
distribution is always bounded by the minimum target dose and
the mean target dose. How close the EUD is to the minimum
target dose depends on the value of a (or SF2). For relatively
radioresistant clonogens (i.e., for large values of SF2 or small
values of a) the EUD tends to the minimum target dose. For
relatively radiosensitive clonogens (i.e., for small values of SF2 or
large values of a) the EUD tends to the mean target dose.
For normal structures we followed the concept of
Damaged Volume (DV) that we investigated while developing
our Critical Volume (CV) Normal Tissue Complication Probabi-
lity (NTCP) model [13]. The concept of DV is based on two
evident experimental facts. First, all normal organs and tissues
have the ability to endure some level of damage caused by
radiation before the clinically relevant manifestation of that
damage occurs. Second, even at the dose levels considered “safe”
for a normal organ some proportion of cells and sub-organ
structures are killed or permanently damaged. A working
hypothesis interpreting these observations is that a clinically
relevant end-point occurs only when the proportion of killed
cells or sub-organ structures exceeds some threshold level. This
threshold level is specific for each normal structure and for each
end-point of interest and is likely to vary in a population of
patients.
Most normal structures are characterized by some tissue
architecture. For example, a kidney is composed of nephrons,
which in turn are composed of tubule cells. For modeling
purposes it is convenient to describe a nephron using a concept
of Functional Sub-Unit (FSU) introduced by Withers [26].
Indeed, it seems that each nephrons represents an independent
structure performing a well-defined function. It was also
observed by Withers that a single surviving tubule cell could
regenerate a whole nephron. A similar well-defined architecture
can be observed for lung with acini and alveoli. Organs or tissues
that are not composed of clearly identifiable functional sub-
structures (e.g., skin) can still be modeled using the same
mathematical framework. That is, one can define an FSU as
the largest volume (or surface in the case of skin) that can be
rescued and repopulated by a single surviving cell.
A mathematical description of the modeling considerations
of the previous paragraph is straightforward. If an FSU can be
rescued by a single surviving cell then the probability of
permanent damage of FSU depends on the dose, D, and the
number of cells per FSU, n, according to binomial statistics as
follows:
PFSU(D, n)=[1–SF(D)]n.
The probability of cell survival as a function of dose, SF(D),
can be calculated using, for example, formula (1), which is based
on the LQ model. For a given inhomogeneous dose distribution
the Damaged Volume (DV) is the proportion of destroyed FSUs.
Assuming that the FSUs are uniformly distributed within the
structure of interest the proportion of destroyed FSUs is the
sum of destroyed FSUs calculated over all voxels within the
structure divided by the total number of voxels m:
m m
DV=1/mS PFSU(Di)=1/mS [1–SF(Di)]n. (3)
i=1 i=1
The same number of FSU's is destroyed when the whole
normal structure is uniformly irradiated to some dose EUD.
Therefore, the following equation must hold:
m
1/mS [1–SF(Di)]n=[1–SF(EUD)]n. (4)
i=1
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This quadratic equation can be solved for EUD:
–––––––––––––––––––
M a a 4EUD=––[– –– + ÷(––)2– –––– ln(1–DV 1–n)], (5)2 b b Mb
where M is the number of fractions. If the cell survival curve is
assumed to be purely exponential (that is, if b is set to zero)
equation (4) becomes linear in dose with a new solution
ln(1–DV 1–n)EUD=– ––––––––––––. (6)a
There are several advantages of the EUD concept. EUD is
a physical dose but it also takes into account the radiosensitivity
of irradiated tumor or normal cells. EUD represents a single
number for each structure of interest and therefore it can be
easily used to compare rival dose distributions. EUD can take
into account not only volume effects but also fractionation
effects [30]. EUD can be used as a single meta-meter of dose
distribution for modeling the probabilities of tissue response to
radiation (i.e., TCP and NTCP). EUD has been successfully
applied to analyzing clinical data [32] and for optimization of
IMRT plans [29, 33]. Figures 2 and 3 show an example of EUD-
based optimized IMRT plan for head and neck cancer compared
with IMRT plans optimized using standard dose and dose-
volume-based objective functions and constraints. This example
has been taken from one of our studies [29]. Figure 2 shows
three dose distributions. Two of them correspond to EUD-based
plans. One represents unrestricted maximization of the target
EUD the other was obtained by assuming that there is some
normal tissue within the target volume with its own tolerance
and the corresponding probability of complication. All plans
show very conformal dose distributions around the target volume
and good sparing of both parotid glands and the spinal cord.
Figures 3a-c show the corresponding DVHs for the target
volume (Figure 3a), parotid glands (Figure 3b), and the spinal
cord (Figure 3c). The EUD-based plans are clearly superior to
the dose and dose-volume-based plan by sparing both critical
normal structures more effectively while at the same time
delivering more dose to the target volume. This was possible
because the EUD-based approach implicitly maximizes the
EUD for the target volume while minimizing the EUDs for the
critical normal structures. The actual objective function that
was used in these optimization examples represents
maximization of the probability of local control and minimization
of the probabilities of toxicity for critical normal structures by
using the corresponding EUDs as variables of the dose-response
functions defined for each VOI [29, 33]. The EUD-based
optimization has the flexibility to explore a much wider space of
possible dose distributions that dose-based optimization. That is,
it can find solutions that may not be found or may not be
apparent when using a dose-based approach.
Figure 2. A color-wash display of dose distribution for a head and neck tumor for three planning approaches described in the text. The corresponding
DVHs are shown in Figure 3.
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Conclusions
Modern radiation therapy planning requires tools that
take into account multidimensional (i.e., volumetric and
temporal) aspects of dose distributions and biological
and clinical consequences of radiation treatment. An
example of such tools, an EUD concept based on cell
survival and tissue architecture, has been described here.
It has been shown here and elsewhere that EUD is useful
for reporting, evaluating and optimizing treatment plans.
The EUD can be used directly to describe the biologically
equivalent dose that each VOI receives under any
(inhomogeneous) treatment conditions. The EUD can
also be used as a meta-meter for modeling the probability
of tumor control and the probability of toxicity for normal
critical organs and tissues.
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